Aarti Drugs: Growth Led by Price Hikes and New Capacity Addition
Aarti Drugs reported revenue growth of 19.7% YoY which stood above our expectations. The API segment grew by 22% while the Speciality Chemical...
322 Views
Aarti Drugs: Low Demand, High RM Prices Impact Profitability; Capex to Drive Growth
We expect revenue and PAT CAGR of 13.3% and 12.3% respectively over the period FY21-FY23E and recommend BUY with TP of Rs 760.
332 Views
India Small Caps: Position for Outperformance Vs Large & Mid Caps
Late Friday evening, the Securities and Exchange Board of Indian
765 Views